ALA Dehydratase Deficient Porphyria (ADP) clinical trials at UCSF
1 in progress, 1 open to new patients
ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)
open to eligible people ages 12 years and up
The purpose of this study is to evaluate the effect of subcutaneous givosiran (ALN-AS1), compared to placebo, on the rate of porphyria attacks in patients with Acute Hepatic Porphyrias (AHP).
San Francisco, California and other locations